Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Hepatology. 2016 Oct 27;64(6):2118–2134. doi: 10.1002/hep.28817

Figure 3. Treatment with the SFK inhibitor PP2 decreases LPS-induced NF-κB activation (A) and cytokine secretion (B) in Cftr-KO cholangiocytes.

Figure 3

Polarized cholangiocytes were treated with PP2 (10 μM), LPS (100 ng/ml) or their combination. A) NF-κB activity was assessed by western blot using an antibody against p65 in nuclear fractions. Histone-3 was used to normalize for the protein content. Bar graphs represent optical density quantification of n=4 experiments. B) Apical and basolateral media were analyzed by Luminex and data were normalized for the cell protein content. Treatment with PP2 significantly inhibited LPS-stimulated cytokine secretion in Cftr-KO cells. The plots represent the means of 5 independent experiments (*p<0.05; **p<0.01).